Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...

ShareHealth, they say is wealth. Sadly, many persons are finding it difficult to access quality health services for various ...

First Lady Mrs Rebecca Akufo-Addo has bid her counterparts in the Organisation of African First Ladies for Development ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Who needs cable? We pit the highest-rated streaming boxes and sticks against one another to find out which one is best for watching shows, movies, and more on your TV. I’ve been PCMag’s home ...

Indian Prime Minister Modi’s recent election victory occurred within a surprisingly tight media space, comprised of the State’s monopoly in radio news and highly concentrated regional newspaper ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Merck MRK will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively.